Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06769464 · ClinicalTrials.gov registry record · NA
Electrophysiological Representations of Odor in the Human Brain Study 1
A NA study of Odor Intensity Ratings, sponsored by Northwestern University.
- Recruiting
- Registry status
- NA
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT06769464: Recruiting NA study of Odor Intensity Ratings, sponsored by Northwestern University.
NCT06769464 is a NA study of Odor Intensity Ratings that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06769464, a NA study of Odor Intensity Ratings, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigating representations of odor intensity in human piriform cortex. To identify a neural representation of perceived odor intensity, it is necessary to dissociate stimulus concentration from perceived intensity. Experiments for this aim will measure human perceptual responses while manipulating intensity independently from concentration using two complementary approaches. In Experiment 1A, we will match perceived intensities across odors of different concentrations, allowing us to identify a neural representation of intensity that is independent of stimulus identity and concentration. In Experiment 1B, we will create conditions of different perceived intensity over constant odor stimuli using adaptation. Approaching the same question from different angles will strengthen the robustness of our findings. Preliminary data suggest that temporal features of the piriform neural response may represent odor intensity.
Primary Outcome
Odors of different concentrations will be presented, and we will obtain behavioral ratings on a GLMS scale of intensity presented on a laptop computer, converted into Matlab for analysis
Conditions Studied
Interventions
- BEHAVIORAL odor
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2028-08-01 |
| Phase | NA |
What NCT06769464 shows while recruiting
NCT06769464 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Odor Intensity Ratings appearing as the primary indexed condition, and to 1 intervention - of which odor is the first listed.
NCT06769464 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06769464 about?
NCT06769464 is a clinical study titled "Electrophysiological Representations of Odor in the Human Brain Study 1". Investigating representations of odor intensity in human piriform cortex. To identify a neural representation of perceived odor intensity, it is necessary to dissociate stimulus concentration from perceived intensity. Experiments for this aim will measure human perceptual responses while manipulatin...
What is the current status of trial NCT06769464?
This trial is currently recruiting. It is a NA study. The enrollment target is 28 participants. The study started on 2024-04-01. Estimated completion is 2028-08-01.
What conditions does trial NCT06769464 study?
This clinical trial studies the following conditions: Odor Intensity Ratings.
What interventions are being tested in trial NCT06769464?
The interventions under investigation include: odor (BEHAVIORAL).
Who is sponsoring clinical trial NCT06769464?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06769464 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06769464's enrollment target sits among peer trials
28 1704th of 2000 higher than 293 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI